Betta Pharmaceuticals Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Public, Subsidiary
- Established
- 2003-01-07
- Employees
- 1.9K
- Market Cap
- -
- Website
- https://www.bettapharma.com
Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06885840
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳The First Hospital of Lanzhou University, Lanzhou, Gansu, China
🇨🇳Dongguan People's Hospital, Dongguan, Guangdong, China
A Phase I Study of CFT8919 in Patients With Advanced NSCLC
- Conditions
- Non-Small Cell Lung Cancer With EGFR Mutation
- Interventions
- Drug: Dose-Escalation (Phase Ia) CFT8919 capsuleDrug: Dose-Expansion (Phase Ib) CFT8919 capsuleDrug: Cohort-Expansion (Phase Ic) CFT8919 capsule
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 166
- Registration Number
- NCT06641609
- Locations
- 🇨🇳
浙江省杭州市拱墅区半山东路1号的英文翻译为： No. 1 Banshan East Road, Gongshu District, Hangzhou, Zhejiang Province, China, Hangzhou, Zhejiang, China
A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06492525
- Locations
- 🇨🇳
The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
- Conditions
- Non-Small Cell Lung CancerEGFR Sensitive MutationAdjuvant Therapy
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 570
- Registration Number
- NCT06041776
- Locations
- 🇨🇳
Peking University International Hospital, Beijing, China
🇨🇳Jiangsu Cancer Hospital, Nanjing, China
🇨🇳Shanghai chest hospital, Shanghai, China
Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation
- Conditions
- Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 172
- Registration Number
- NCT06015568
- Locations
- 🇨🇳
The first affiliated hospital of bengbu medical college, Bengbu, Anhui, China
🇨🇳Hunan cancer hospital, Changsha, Hunan, China
🇨🇳Shanghai chest hospital, Shanghai, China
BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 388
- Registration Number
- NCT05869240
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
A Study of BPI-452080 in Subjects With Solid Tumors
- Conditions
- Renal Cell CarcinomaSolid TumorVon Hippel-Lindau Disease
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 87
- Registration Number
- NCT05843305
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳West China Hospital of Sichuan University, Chengdu, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, China
A Study of BPI-460372 in Advanced Solid Tumor Patients
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 82
- Registration Number
- NCT05789602
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Affiliated Hospital of Hebei University, Baoding, Hebei, China
A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 274
- Registration Number
- NCT05433480
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients
- Conditions
- Non-small Cell Lung CancerPancreatic CancerColorectal CancerSolid Tumor
- Interventions
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 230
- Registration Number
- NCT05369312
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Sun yat-sen university, Guangzhou, Guangdong, China
🇨🇳Henan Tumor Hospital, Zhengzhou, Henan, China